Trial Profile
A Phase II, International, Multicenter, Open-label, Proof of Concept Study of BN83495 in Postmenopausal Women With Advanced, Metastatic or Recurrent Oestrogen Receptor (ER) Positive Endometrial Carcinoma Who Have Received One Line of Chemotherapy in the Adjuvant or Metastatic Setting.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Irosustat (Primary)
- Indications Endometrial cancer
- Focus Therapeutic Use
- Sponsors Ipsen
- 06 Jun 2011 Status changed from recruiting to discontinued.
- 07 Dec 2010 New trial record